NCT00189696已完成3 期
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 试验地点
- 4
研究概览
简要总结
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients satisfying the Rome II Diagnostic Criteria.
- •Patients in whom no organic changes were observed in large intestine.
排除标准
- •Patients have diseases which interfere with evaluation of the efficacy and safety in this study.
- •Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)Irritable Bowel SyndromeNCT00189813Astellas Pharma Inc691
已完成
3 期
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel SyndromeDiarrhea-predominant Irritable Bowel SyndromeNCT01736423Astellas Pharma Inc151
已完成
2 期
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female PatientsIrritable Bowel SyndromeNCT01274000Astellas Pharma Inc409
已完成
1 期
The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy SubjectsHealthyNCT03655873Sunshine Lake Pharma Co., Ltd.43
已完成
不适用
A clinical study of the efficacy of 5HT3 receptor antagonist (palonocetron) in malignant lymphoma patients treated with (R-)CHOP regimeMalignant LymphomaJPRN-UMIN000011092Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan50